Literature DB >> 23904308

Tonsillar Kaposi sarcoma in a patient with membranous glomerulonephritis on immunosuppressive therapy.

Nabeel Al-Brahim1, Ashraf H Zaki, Khaled El-Merhi, Mahmoud S Ahmad.   

Abstract

Kaposi sarcoma is a malignant vascular neoplasm uncommonly seen in immunosuppressed patients. Herein we report an unusual case of tonsillar Kaposi sarcoma in a patient with membranous glomerulonephritis treated with prednisolone and cyclosporine. The patient presented after 10 months of starting the treatment with a tonsillar mass. Histological examination was typical of monomorphic spindle cell proliferation with slit-like vascular channels. The tumor cells expressed CD34, D2-40 and positive nuclear stain for HHV-8. Kaposi sarcoma is associated with immunosuppression and rarely occurs in the tonsil. Clinicians should be aware of this rare presentation of Kaposi sarcoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904308     DOI: 10.1177/014556131309200712

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  3 in total

1.  Isolated kaposi sarcoma of the tonsil: a case report and review of the scientific literature.

Authors:  Barbara Pittore; Carlo Loris Pelagatti; Francesco Deiana; Francesco Ortu; Elena Maricosu; Sergio Cossu; Giovanni Sotgiu
Journal:  Case Rep Otolaryngol       Date:  2015-02-10

2.  Primary Kaposi's sarcoma of the nasal cavity: a case report and review of the literature.

Authors:  Karima Mouden; Mouna Khmou; Saida Loughmari; Afaf Semmar; Hanan El Kacemi; Basma El Khannoussi; Tayeb Kebdani; Sanaa Elmajjaoui; Noureddine Benjaafar
Journal:  Clin Sarcoma Res       Date:  2016-03-17

3.  Steroids are a risk factor for Kaposi's sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection.

Authors:  Mónica Fernández-Sánchez; María C Iglesias; Yuria Ablanedo-Terrazas; Christopher E Ormsby; Claudia Alvarado-de la Barrera; Gustavo Reyes-Terán
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.